A Narrative Exploration of Psilocybin's Potential in Mental Health

Overview

Journal Front Psychiatry

Specialty Psychiatry

Date 2024 Nov 14

PMID 39540010

Authors

Huitae Min

Soon Young Park

Jisu Park

Seongsu Na

Hoe-Suk Lee

Taejung Kim

Jungyeob Ham

Young-Tae Park

Affiliations

Soon will be listed here.

Abstract

Psilocybin, a psychoactive substance, has recently garnered attention for its high therapeutic potential in psychiatry. In this study, we investigated the multifaceted aspects of psilocybin, highlighting its chemical properties, mechanisms of action, and burgeoning role in psychiatric treatment. Furthermore, we examined the clinical applications and potential therapeutic benefits of psilocybin in the treatment of various mental health disorders, supported by accumulating clinical evidence. This review aims to deepen our understanding of the clinical impact of psilocybin, elucidate its therapeutic value, and propose directions for future research, thereby paving the way for its integration into mainstream psychiatric treatments. Psilocybin has been shown to be safe in clinical trials with manageable side effects. However, additional safety measures are required after this discussion, including dosing protocols, patient monitoring, and distress management strategies.

References

Barrett F, Doss M, Sepeda N, Pekar J, Griffiths R . Emotions and brain function are altered up to one month after a single high dose of psilocybin. Sci Rep. 2020; 10(1):2214. PMC: 7010702. DOI: 10.1038/s41598-020-59282-y. View

Johnson M, Griffiths R, Hendricks P, Henningfield J . The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology. 2018; 142:143-166. PMC: 6791528. DOI: 10.1016/j.neuropharm.2018.05.012. View

Shah F, Shehzadi S, Akram F, Ul Haq I, Javed B, Sabir S . Unveiling the Psychedelic Journey: An Appraisal of Psilocybin as a Profound Antidepressant Therapy. Mol Biotechnol. 2023; 67(1):36-53. DOI: 10.1007/s12033-023-00994-7. View

Khan A, Bradley E, ODonovan A, Woolley J . Psilocybin for Trauma-Related Disorders. Curr Top Behav Neurosci. 2022; 56:319-332. DOI: 10.1007/7854_2022_366. View

Peck S, Shao S, Gruen T, Yang K, Babakanian A, Trim J . Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study. Nat Med. 2023; 29(8):1947-1953. PMC: 10427429. DOI: 10.1038/s41591-023-02455-9. View

Nayak S, Jackson H, Sepeda N, Mathai D, So S, Yaffe A . Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey. Front Psychiatry. 2023; 14:1199642. PMC: 10545967. DOI: 10.3389/fpsyt.2023.1199642. View

Flower J, Gibbons Jr W, Adams A, Wang X, Broude C, Jones J . "Biosynthesis of psilocybin and its nonnatural derivatives by a promiscuous psilocybin synthesis pathway in Escherichia coli". Biotechnol Bioeng. 2023; 120(8):2214-2229. DOI: 10.1002/bit.28480. View

Schindler E . Psychedelics in the Treatment of Headache and Chronic Pain Disorders. Curr Top Behav Neurosci. 2022; 56:261-285. DOI: 10.1007/7854_2022_365. View

Fett A, Viechtbauer W, Dominguez M, Penn D, van Os J, Krabbendam L . The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. Neurosci Biobehav Rev. 2010; 35(3):573-88. DOI: 10.1016/j.neubiorev.2010.07.001. View

10.

Pokorny T, Preller K, Kometer M, Dziobek I, Vollenweider F . Effect of Psilocybin on Empathy and Moral Decision-Making. Int J Neuropsychopharmacol. 2017; 20(9):747-757. PMC: 5581487. DOI: 10.1093/ijnp/pyx047. View

11.

Brown R, Nicholas C, Cozzi N, Gassman M, Cooper K, Muller D . Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults. Clin Pharmacokinet. 2017; 56(12):1543-1554. DOI: 10.1007/s40262-017-0540-6. View

12.

Gattuso J, Perkins D, Ruffell S, Lawrence A, Hoyer D, Jacobson L . Default Mode Network Modulation by Psychedelics: A Systematic Review. Int J Neuropsychopharmacol. 2022; 26(3):155-188. PMC: 10032309. DOI: 10.1093/ijnp/pyac074. View

13.

Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R . Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med. 2021; 384(15):1402-1411. DOI: 10.1056/NEJMoa2032994. View

14.

Kraehenmann R, Preller K, Scheidegger M, Pokorny T, Bosch O, Seifritz E . Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers. Biol Psychiatry. 2014; 78(8):572-81. DOI: 10.1016/j.biopsych.2014.04.010. View

15.

Davis A, Barrett F, May D, Cosimano M, Sepeda N, Johnson M . Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2020; 78(5):481-489. PMC: 7643046. DOI: 10.1001/jamapsychiatry.2020.3285. View

16.

Cuijpers P, van Straten A, van Schaik A, Andersson G . Psychological treatment of depression in primary care: a meta-analysis. Br J Gen Pract. 2009; 59(559):e51-60. PMC: 2629842. DOI: 10.3399/bjgp09X395139. View

17.

Marzola E, Nasser J, Hashim S, Shih P, Kaye W . Nutritional rehabilitation in anorexia nervosa: review of the literature and implications for treatment. BMC Psychiatry. 2013; 13:290. PMC: 3829207. DOI: 10.1186/1471-244X-13-290. View

18.

May A, Schwedt T, Magis D, Pozo-Rosich P, Evers S, Wang S . Cluster headache. Nat Rev Dis Primers. 2018; 4:18006. DOI: 10.1038/nrdp.2018.6. View

19.

Chevallier C, Kohls G, Troiani V, Brodkin E, Schultz R . The social motivation theory of autism. Trends Cogn Sci. 2012; 16(4):231-9. PMC: 3329932. DOI: 10.1016/j.tics.2012.02.007. View

20.

Nichols D . Psilocybin: from ancient magic to modern medicine. J Antibiot (Tokyo). 2020; 73(10):679-686. DOI: 10.1038/s41429-020-0311-8. View